Ondine Biomedical, Inc. (GB:OBI) has released an update.
Ondine Biomedical Inc. announces the successful completion of its fundraising efforts, securing approximately £3.04 million in gross proceeds, which translates to an estimated net of £2.92 million. The placement attracted both new and existing investors, with the issue price set at a 36.6% premium over the previous closing mid-price. Alongside the fundraising, the company will issue warrants and expects the new common shares to begin trading on AIM around May 9, 2024.
For further insights into GB:OBI stock, check out TipRanks’ Stock Analysis page.
